Veeva Systems (VEEV) is a cloud software company built entirely around the global life sciences industry. The company generated $3.195 billion in revenue in fiscal year 2026, growing 16% year over year, at a 44.9% non-GAAP operating margin, with $6.6 billion in cash and zero debt. It serves 1,552 customers, essentially every major pharmaceutical and biotech company on earth. The stock is down approximately 37% from its 52-week high.
The reason the stock is where it is comes down to one product: CRM. Veeva built its original sales force software on Salesforce’s infrastructure, not its own. In 2022, Veeva announced it was rebuilding CRM from scratch on its proprietary Vault platform, a multi-year migration of approximately 627 remaining customers that has to run alongside normal business operations. Salesforce, facing the loss of Veeva’s revenue from its hosted platform, responded by partnering with IQVIA in April 2024 to compete directly for those same customers. The commercial segment is already contested. The migration will determine how much of it Veeva retains, and whether Vault CRM, once complete, closes the competitive window or leaves it permanently open.
Salesforce’s response, partnering with a competitor specifically to retain Veeva’s customers, reads less like competitive innovation and more like a company that assumed a marquee partner’s customer base was permanently accessible revenue. Veeva apparently disagreed. It is also worth asking what that response tells other companies that have built vertically on Salesforce’s platform. When the relationship became inconvenient for Salesforce, they partnered with a competitor. That dynamic does not go unnoticed in enterprise IT.
Salesforce has the enterprise contracts to win some customers on procurement arguments alone. But Salesforce is a $37 billion horizontal platform company with limited organizational incentive to go deep in a single regulated vertical; the more durable competitive threat is IQVIA, which has both the pharma domain expertise and a direct motive. For now, the market is treating the uncertainty around the migration as a reason to reprice 17 years of compounding. Whether that repricing is an opportunity or a warning is what this post tries to work out.
What Veeva Does
Veeva provides cloud software, data, and business consulting to the global life sciences industry. Its customers are pharmaceutical companies, biotechs, and medical device makers. Veeva does not sell to hospitals, payers, or consumers. Every dollar of revenue comes from companies that develop and commercialize drugs or medical devices.
The company operates in two reportable segments. Commercial Solutions (~47% of FY2026 subscription revenue) provides software and data for everything that happens after a drug is approved, including managing the sales force, running marketing campaigns, tracking regulatory submissions, and measuring media effectiveness. R&D Solutions (~53% of FY2026 subscription revenue, growing faster) provides software for everything that happens before approval, including clinical trial management, regulatory submissions, quality systems, and safety reporting.
Subscription services represented 84% of FY2026 total revenue at an 86% gross margin. Professional services represented 16% at an 18% gross margin. The professional services business is not run for profit; it exists to drive platform adoption and expansion.
The Vault Platform
Vault is Veeva’s proprietary cloud platform and the architectural foundation of the entire business. It handles both structured data and unstructured content, including documents, records, and relational data, all within the same environment. This is technically difficult to build and creates the stickiness that makes Veeva hard to displace.
Every major Veeva application runs on Vault: eTMF (the document repository for a clinical trial), RIM (regulatory information management), Safety (adverse event management), QMS (quality management), PromoMats (promotional content lifecycle), and, as of 2022, Vault CRM. A life sciences company that runs three Vault applications has its clinical, regulatory, and quality data in a shared environment. Migrating off requires re-validating every system against FDA 21 CFR Part 11 and EU GMP Annex 11, a process that takes 12 to 18 months and costs millions. No procurement team initiates that process lightly.
Veeva’s original CRM product was not built on Vault. It was built on Salesforce’s Force.com platform. That distinction is the source of every significant near-term risk the company faces.
Commercial Cloud
The Commercial Cloud includes CRM, content management, and data products used by pharma sales reps, medical affairs teams, and marketing organizations.
Vault CRM is Veeva’s next-generation CRM, rebuilt from scratch on the Vault platform. It replaces the legacy Veeva CRM, which runs on Salesforce infrastructure. As of Q4 FY2026, more than 125 customers have gone live on Vault CRM, including 2 top-20 biopharmas in major markets, with 10 of the top 20 biopharmas committed globally and approximately 14 expected to commit. Veeva has 767 total Commercial Solutions customers; approximately 627 still need to migrate before Salesforce’s end-of-support date of December 2029.
Campaign Manager and Service Center are new commercial products available only on Vault CRM, giving customers additional reasons to complete the migration and giving Veeva incremental revenue per seat.
Veeva PromoMats manages the lifecycle of promotional content, covering creation, medical/legal/regulatory review, approval, distribution, and expiration for every piece of external-facing material a pharma company produces.
Veeva Medical centralizes medical content and inquiry management for medical affairs teams, which operate separately from commercial sales but face similar regulatory content requirements.
The commercial segment is growing slower than R&D. In FY2025, commercial subscription revenue grew approximately 9% year over year. R&D subscription revenue grew approximately 21%.
R&D Cloud
The R&D Cloud covers the clinical, regulatory, and quality software that drug companies use from early development through manufacturing.
| Product | Function |
|---|---|
| Vault eTMF | Electronic Trial Master File, the central document repository required for every clinical trial |
| Vault EDC | Electronic data capture for clinical trials |
| Vault CTMS | Clinical trial management system |
| Vault CDB | Clinical data aggregation and cleaning |
| Vault RIM | Regulatory information management, including submissions, approvals, and registrations globally |
| Vault Safety | Adverse event intake, processing, and regulatory submission |
| Vault QMS | Quality management system for GMP-regulated manufacturing |
| Vault Quality Docs | Document management for quality systems |
| Training Solutions | GMP training compliance |
The R&D segment crossed 50% of total subscription revenue in FY2025 and is widening. Veeva’s penetration in clinical and regulatory software is lower than in CRM, meaning the growth runway is longer. The clinical trial software market is fragmented, with Oracle and IQVIA holding legacy positions that Veeva has been displacing.
Quality Cloud is also expanding into adjacent industries, including consumer products, industrial, and other regulated manufacturers, providing a growth vector outside life sciences proper.
Data Cloud
Veeva’s data products sit within the Commercial segment and represent a structurally different type of competitive advantage from the software applications.
Veeva OpenData is a master reference database of every healthcare professional globally, covering demographics, specialty, license, institutional affiliations, and contact information. This is the “phonebook” that pharma sales teams use to target the right physicians. Its accuracy improves as customers use and correct it, creating a network effect that makes it progressively harder for competitors to replicate.
Veeva Compass is a de-identified patient-level dataset of longitudinal prescription and medical claims data. Pharma companies use it for sales force sizing, territory design, targeting, and incentive compensation calculations. Compass competes directly with IQVIA’s data assets, and that competition is the most actively contested part of Veeva’s business.
Crossix measures the effectiveness of pharmaceutical media campaigns using patient-level data, connecting an ad impression to an actual prescription fill. Crossix had an outstanding year in FY2026 and has become a meaningful revenue contributor.
The Salesforce Migration in Detail
Veeva’s legacy CRM was built on Salesforce’s Force.com platform. Peter Gassner came out of Salesforce in 2007 and built Veeva CRM on the infrastructure he knew. That decision gave Veeva a fast path to market in 2008, but it created a structural dependency: Veeva pays Salesforce hosting fees, Salesforce has full visibility into Veeva’s commercial customer base, and Veeva cannot fully control the product roadmap of a platform it doesn’t own.
In 2022, Veeva announced it would build Vault CRM as a complete replacement, entirely on its own infrastructure. Salesforce set an end-of-support date for Veeva CRM, updated in early 2026 to December 2029, pulled in roughly eight months from the prior September 2030 date, reflecting strong Vault CRM momentum. Life sciences companies run FDA-validated systems under 21 CFR Part 11, which requires software to be current and supported. Running on an unsupported platform creates regulatory audit exposure, which gives customers real urgency to complete the migration well before the deadline rather than at it.
In April 2024, Salesforce and IQVIA announced an expanded strategic partnership to offer a competing life sciences CRM. The IQVIA partnership gives Salesforce life sciences workflow expertise it did not have; IQVIA gains access to Salesforce’s infrastructure and CRM architecture. Whether that partnership produces a product good enough to peel away Veeva’s customers, or whether it is two large organizations with misaligned incentives building something neither would have built alone, is one of the open questions of the next three years.
The migration status as of Q4 FY2026:
| Metric | Status |
|---|---|
| Customers live on Vault CRM | 125+ (actual closer to 140 per management) |
| Top-20 biopharmas committed globally | 10 committed; ~14 expected |
| Customers still on legacy Salesforce-hosted CRM | ~627 of 767 total Commercial Solutions customers |
| Salesforce end-of-support | December 2029 |
| New Vault CRM-only products | Campaign Manager, Service Center |
The bull case on the migration: Vault CRM consolidates all commercial data, including CRM activity, content, and field messaging, onto the same Vault platform already used for regulatory and quality applications. When that consolidation is complete, the commercial segment will be more tightly integrated with the R&D segment than it has ever been, and switching costs will increase substantially. Completing the migration also eliminates the Salesforce infrastructure cost, improving operating margins.
The bear case: migrating approximately 627 remaining customers over nearly four years, while a credible competitor is actively recruiting them to stay on Salesforce, is a real operational risk. Any high-profile customer that defects publicly changes the narrative. The migration is running on schedule, but the window to December 2029 is finite.
One additional piece of context: CRM represents approximately 20% of Veeva’s revenue today and is expected to be roughly 10% by the 2030 timeframe, not because CRM is shrinking, but because the rest of the business is growing faster. The migration risk is real, but the segment’s relative weight is declining by design.
Public Benefit Corporation
Veeva converted to a Delaware Public Benefit Corporation in February 2021, requiring a shareholder vote. It was the first publicly traded company to do so and remains the largest by market cap. As a PBC, the board is legally required to balance stockholder financial interests against the interests of customers, employees, partners, and communities. The stated public benefit purpose is “to provide products and services that are intended to help make the industries we serve more productive, and to create high-quality employment opportunities in the communities in which we operate.”
Veeva does not require any employee anywhere in the world to sign a non-compete agreement. This is stated explicitly in the 10-K and reflects the PBC structure in practice.
From an investor standpoint, the PBC designation is most significant for what it prevents: a short-term activist campaign demanding margin extraction at the expense of product investment or customer relationships would face a board with a legal basis to push back. Whether that protection matters depends on whether you believe Veeva’s long-term reinvestment is value-creating, which the last 17 years of results suggest it is.
Financial Profile
Veeva’s fiscal year ends January 31. All figures below are FY2026 (ending January 31, 2026) unless noted.
Income Statement
| Metric | FY2026 | FY2025 | Growth |
|---|---|---|---|
| Total Revenue | $3,195M | $2,747M | +16% |
| Subscription Revenue | $2,684M | $2,285M | +17% |
| Professional Services | $511M | $462M | +11% |
| Subscription Gross Margin | ~86% | ~86% | flat |
| Non-GAAP Operating Income | $1,434M | $1,152M | +24% |
| Non-GAAP Operating Margin | 44.9% | 41.9% | +300 bps |
| Non-GAAP EPS | $8.10 | $6.60 | +23% |
| GAAP EPS | $5.44 | $4.32 | +26% |
Balance Sheet and Cash Generation
| Metric | Amount |
|---|---|
| Cash and investments | ~$6.6B |
| Total debt | $0 |
| Operating cash flow (FY2026) | $1,390M |
| Operating cash flow margin | 43.5% |
| Share repurchase authorization | $2.0B (January 2026) |
Operating Expense Structure (FY2025, most recent full filing)
| Line | Amount | % of Revenue |
|---|---|---|
| Research & Development | $693M | 25% |
| Sales & Marketing | $397M | 14% |
| General & Administrative | $266M | 10% |
R&D at 25% of revenue is high for a company at this scale. It reflects ongoing investment in Vault, the Vault CRM build-out, and AI capabilities. The company does not cut R&D to meet short-term earnings expectations.
FY2027 Guidance (issued with Q4 FY2026 results)
| Metric | Guidance |
|---|---|
| Total Revenue | $3,585–3,600M (+~13%) |
| Non-GAAP Operating Income | ~$1,590M |
| Non-GAAP EPS | ~$8.85 |
| Q1 FY2027 Revenue | $855–858M (+13%) |
The deceleration from 16% to 13% guidance is partially attributable to the migration transition period. As Vault CRM seats go live, implementation revenue from the migration itself rolls off, while subscription revenue from the new platform builds.
Valuation
Veeva trades at approximately $195 per share as of March 10, 2026, against a fully diluted share count of approximately 165 million shares, implying a market cap of approximately $32 billion. Net cash of $6.6 billion reduces enterprise value to approximately $25.4 billion.
| Metric | Value |
|---|---|
| Market Cap | ~$32B |
| Enterprise Value (net of cash) | ~$25.4B |
| 52-week range | $168.14–$310.50 |
| NTM Revenue (FY2027 guidance midpoint) | $3,592M |
| NTM Non-GAAP EPS | ~$8.85 |
| P/E (NTM non-GAAP) | ~22x |
| EV/NTM Revenue | ~7.1x |
| EV/NTM Non-GAAP Operating Income | ~16x |
| P/FCF (trailing $1,390M OCF) | ~23x |
For context, Veeva grew revenue 16% in FY2026 at a 44.9% non-GAAP operating margin, with 86% subscription gross margins, zero debt, $6.6 billion in cash, and a $2 billion buyback program. The business has generated positive free cash flow every year since 2013 and has never had a down revenue year as a public company.
The 22x forward non-GAAP P/E is the lowest valuation the stock has traded at in the past several years. That compression reflects the growth deceleration from 16% to 13% guidance and investor uncertainty about the CRM migration outcome.
Scenario Analysis
Three scenarios, anchored to FY2027 guidance and the $8.85 non-GAAP EPS estimate:
| Scenario | Conditions | P/E Applied | Price Target |
|---|---|---|---|
| Bear (~$165–185) | CRM migration causes material churn; growth decelerates to 7–9%; multiple compresses toward software sector average | 19–21x | $168–186 |
| Base (~$220–250) | Migration executes on schedule with modest churn; R&D sustains 15%+ growth; buyback reduces share count by 3–4% annually; steady beat-and-raise | 25–28x | $221–248 |
| Bull (~$290–330) | Migration is seamless; AI Agents monetize meaningfully; Crossix accelerates; Vault CRM adds incremental revenue from Campaign Manager and Service Center | 33–37x | $292–327 |
The bear case implies the stock is approximately where it should be. The base case implies approximately 15–25% upside over 12–18 months. The bull case requires execution on multiple fronts simultaneously and a multiple re-rating that may require a full migration completion narrative.
At the $168 52-week low (roughly 19x forward non-GAAP EPS), the market is effectively pricing in meaningful migration-related churn. Whether that discount is warranted is the core investment question.
What to Watch
| Catalyst | Why It Matters | Timeline |
|---|---|---|
| Vault CRM customer additions (quarterly) | Rate of migration is the single most important leading indicator for the commercial segment; need to see ~627 remaining customers migrate by December 2029 | Each earnings release |
| Any disclosed high-profile competitive loss | One visible defection to Salesforce/IQVIA would meaningfully reset market confidence in the migration narrative | Ongoing |
| R&D subscription growth rate | Needs to sustain 15%+ to offset commercial transition pressure; any deceleration below 12% would pressure total growth guidance | Each earnings release |
| AI Agent monetization | Veeva AI Agents launched December 2025; commercial traction, quantified in ARR terms, would provide a new growth lever not in current guidance | FY2027 earnings calls |
| Buyback execution | $2B authorization against a $32B market cap is meaningful; pace of repurchase signals management’s view of current valuation | Each earnings release |
| Q1 FY2027 earnings | First quarter test of the 13% guidance; any shortfall would accelerate the multiple compression narrative | ~June 2026 (date not yet confirmed) |
| FY2026 10-K filing | Expected approximately March 24, 2026; will include full segment breakout, complete balance sheet, and any new disclosures on the migration | ~March 24, 2026 |
IQVIA and Salesforce Expand Global Partnership (April 8, 2024)
Veeva Defied Detractors When It Launched a Cloud Life Sciences Business (TechCrunch, 2017)
How Veeva Hit $100M ARR With Just $3M Raised (SaaStr)
Peter Gassner (Wikipedia)
Veeva Systems Q4 FY2026 Earnings Release (March 4, 2026)
Veeva Systems 10-K FY2025 (March 24, 2025)
Research and analysis conducted with AI assistance using SEC EDGAR filings as primary sources.